---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024119"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:25:18.073369+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pure Bioscience raises $1.015M via convertible notes from accredited investors

## Summary
- Issued convertible promissory notes for $1.015M initial principal; potential subsequent closings up to $1.8M total.
- Notes bear 7.55% annual interest, mature in three years, convertible at 30-day VWAP with $0.15 floor and $0.23 cap.
- Board members Tom Y. Lee and Ivan Chen invested $1,000,000 and $15,000 respectively.
- Notes sold in private placement under Section 4(a)(2); disinterested board approved.

## SEC filing metadata
- accession: 0001493152-23-024119
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315223024119/0001493152-23-024119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315223024119/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024119
- JSON: https://secwatch.observer/filing/0001493152-23-024119.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024119.txt

## Key facts
- Debt Financings
  PURE BIOSCIENCE, INC. incurred convertible notes of $1,015,000 at 7.55% maturing third-year anniversary of the date of issuance.
  - Instrument: convertible notes
  - Principal: $1,015,000
  - Rate: 7.55%
  - Maturity: third-year anniversary of the date of issuance
  - Event: incurrence
  source text: On July 3, 2023, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $1,015,000 (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223024119/0001493152-23-024119-index.htm
- Material Agreements
  PURE BIOSCIENCE, INC. entered into Note Purchase Agreement with certain accredited investors valued at $1,015,000 (effective 2023-07-03).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: certain accredited investors
  - Value: $1,015,000
  - Effective: 2023-07-03
  source text: On July 3, 2023, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $1,015,000 (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315223024119/0001493152-23-024119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.